Abstract
Background: The gender disparity in incidence, aggressiveness and prognosis is well established for thyroid cancer but the cause of the disparity is poorly understood. Objective: The main objective of the study was to evaluate the gender difference in thyroid disease. Materials and Methods: This cross sectional study was conducted in the Department of Otolaryngology-Head & Neck Surgery of Bangabandhu Sheikh Mujib Medical University, Dhaka from January 2013 to December 2015. The thyroid gland was assessed by palpation in all patients. Estimation of serum TSH concentrations were performed by automated immune chemiluminescent assay. Results: In this study out of 400 thyroid cancer patients, 327 were females and 73 were males. The mean age was almost similar between male and female patients (p=0.245). HOMA-IR was significant higher in female patients than male patients (1.9±0.5 vs 1.7±0.6). FT3, FT4 and TPO antibody were significantly higher in male patients than female patients, whereas TSH level was significantly higher in female patients than male patients (5.7±2.9 vs 4.5±2.8 µIU/mL). In multivariate logistic regression analysis abnormal TSH patient had 3.61 (95% CI 1.66 to 7.81) times more likely to have female. Abnormal FT3 patient had 2.56 (95% CI 1.08 to 6.05) times more likely to have female. Abnormal TSH and FT3 were significantly associated with female patients. Conclusion: Serum TSH and FT3 levels were significantly associated with thyroid cancer especially for females. Our results suggest the necessity of monitoring TSH and FT3 in the population for thyroid cancer risk assessment, especially female.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call